Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Annovis BioANVS -2.46%30 3-1 Month Momentum % is 9.88% as of Sep. 10, 2026. GuruFocus rates ANVS with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 1,382 Biotechnology companies, Annovis Bio ranks better than 60.56% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-10), Annovis Bio's 3-1 Month Momentum % is 9.88%.
The industry rank for Annovis Bio's 3-1 Month Momentum % or its related term are showing as below:
ANVS's 3-1 Month Momentum % is ranked better than 60.56% of 1382
companies
in the Biotechnology industry
Industry Median: 1.21
vs ANVS: 9.88
Annovis Bio (NYSE:ANVS) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Annovis Bio 3-1 Month Momentum % Related Terms
ANVS vs CRDF, ELTX, LONA: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Annovis Bio's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Annovis Bio 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Annovis Bio's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Annovis Bio's 3-1 Month Momentum % falls into.
Annovis Bio (NYSE:ANVS) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Annovis Bio (ANVS) has a 3-1 Month Momentum % of 9.88% as of Sep. 10, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Annovis Bio and its competitors. According to the industry distribution chart, Annovis Bio ranks #545 out of 1382 companies in the Biotechnology industry, placing it in the top 39.4%.
Is Annovis Bio's 3-1 Month Momentum % too high?
Annovis Bio's current 3-1 Month Momentum % is 9.88%. The Biotechnology industry median 3-1 Month Momentum % is 1.21. Annovis Bio's value of 9.88% is 716.5% above this industry median. Based on the distribution chart, Annovis Bio ranks #545 out of 1382 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Annovis Bio has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Annovis Bio's 3-1 Month Momentum % compare to CRDF and ELTX?
According to the Biotechnology industry distribution chart, Annovis Bio ranks #545 out of 1382 companies for 3-1 Month Momentum %. This puts Annovis Bio in the upper half of its industry. The industry median 3-1 Month Momentum % is 1.21. Annovis Bio's value of 9.88% is 716.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
The median 3-1 Month Momentum % among Biotechnology companies is 1.21, based on 1,382 companies in the industry. Companies in the top quartile (top 25%) have a 3-1 Month Momentum % significantly above this median, while those in the bottom quartile fall well below. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Annovis Bio's current 3-1 Month Momentum % of 9.88% is 716.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Annovis Bio and its competitors. For the Biotechnology industry, the median 3-1 Month Momentum % is 1.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Annovis Bio's current 3-1 Month Momentum % is 9.88%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Annovis Bio stock overvalued right now?
Annovis Bio (ANVS) has a current 3-1 Month Momentum % of 9.88%. The current 3-1 Month Momentum % is 9.88% and 716.5% above the Biotechnology industry median of 1.21. Annovis Bio's overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Annovis Bio (ANVS), the current 3-1 Month Momentum % is 9.88% as of Sep. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.
30GF Score
Get the complete analysis for ANVS
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ANVS has been successfully added to your 
